These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
Pubmed for Handhelds
PUBMED FOR HANDHELDS
Journal Abstract Search
117 related items for PubMed ID: 490428
1. A biochemical measure of monoamine oxidase type A and B inhibitor effects in man. Campbell IC, Shiling DJ, Lipper S, Slater S, Murphy DL. J Psychiatr Res; 1979; 15(2):77-84. PubMed ID: 490428 [No Abstract] [Full Text] [Related]
5. The nature of the inhibition of rat liver monoamine oxidase types A and B by the acetylenic inhibitors clorgyline, l-deprenyl and pargyline. Fowler CJ, Mantle TJ, Tipton KF. Biochem Pharmacol; 1982 Nov 15; 31(22):3555-61. PubMed ID: 6817759 [Abstract] [Full Text] [Related]
6. Chronic clorgyline and pargyline increase apomorphine-induced stereotypy in the rat. Campbell IC, Durcan MJ, Cohen RM, Pickar D, Chugani D, Murphy DL. Pharmacol Biochem Behav; 1985 Dec 15; 23(6):921-5. PubMed ID: 4080777 [Abstract] [Full Text] [Related]
7. On the dual nature of monoamine oxidase. Knoll J. Horiz Biochem Biophys; 1978 Dec 15; 5():37-64. PubMed ID: 355087 [No Abstract] [Full Text] [Related]
8. Inhibition of monoamine oxidase by clorgyline and deprenyl in circumventricular structures of rat brain. Kinemuchi H, Wakui Y, Arai Y, Kamijo K. Biochem Pharmacol; 1980 Oct 15; 29(20):2871-4. PubMed ID: 6776962 [No Abstract] [Full Text] [Related]
9. Dopamine is a monoamine oxidase B substrate in man. Glover V, Sandler M, Owen F, Riley GJ. Nature; 1977 Jan 06; 265(5589):80-1. PubMed ID: 834248 [No Abstract] [Full Text] [Related]
11. Species differences in the deamination of dopamine and other substrates for monoamine oxidase in brain. Garrick NA, Murphy DL. Psychopharmacology (Berl); 1980 Jan 06; 72(1):27-33. PubMed ID: 6781004 [No Abstract] [Full Text] [Related]
12. The acetylenic monoamine oxidase inhibitors clorgyline, deprenyl, pargyline and J-508: their properties and applications. Fowler CJ, Oreland L, Callingham BA. J Pharm Pharmacol; 1981 Jun 06; 33(6):341-7. PubMed ID: 6115003 [No Abstract] [Full Text] [Related]
13. Lipid substitution of mitochondrial monoamine oxidase can lead to the abolition of clorgyline selective inhibition without alteration in the A/B ratio assessed by substrate utilisation. Houslay MD. Biochem Pharmacol; 1980 Dec 01; 29(23):3211-3. PubMed ID: 7447959 [No Abstract] [Full Text] [Related]
14. The effects of chronic regimens of clorgyline and pargyline on monoamine metabolism in the rat brain. Campbell IC, Robinson DS, Lovenberg W, Murphy DL. J Neurochem; 1979 Jan 01; 32(1):49-55. PubMed ID: 32233 [No Abstract] [Full Text] [Related]
15. The metabolism of indolealkylamines by type A and B monoamine oxidase of brain. Neff NH, Yang HY, Goridis C, Bialek D. Adv Biochem Psychopharmacol; 1974 Jan 01; 11(0):51-8. PubMed ID: 4845688 [No Abstract] [Full Text] [Related]
16. Molecular turnover numbers of different forms of mitochondrial monoamine oxidase in rat. Egashira T, Ekstedt B, Kinemuchi H, Wiberg A, Oreland L. Med Biol; 1976 Aug 01; 54(4):272-7. PubMed ID: 957813 [Abstract] [Full Text] [Related]
17. Effect of the monoamine oxidase inhibitors clorgyline and pargyline on the hyperphagia of obese mice. Feldman JM. Behav Brain Res; 1988 Jul 01; 29(1-2):147-58. PubMed ID: 2840925 [Abstract] [Full Text] [Related]
18. Phenylethanolamine is a specific substrate for type B monoamine oxidase. Edwards DJ. Life Sci; 1978 Sep 18; 23(11):1201-7. PubMed ID: 713694 [No Abstract] [Full Text] [Related]